Silvergate announced the launch of Epaned Oral Solution (enalapril) indicated for the treatment of hypertension in patients aged ≥1 month old, and in adults, for symptomatic heart failure and asymptomatic left ventricular dysfunction.
Epaned is the first enalapril oral solution approved by the Food and Drug Administration (FDA). The ready-to-use solution minimizes the risk for errors as it does not require mixing, and it does not require refrigeration after dispensing. The solution allows for consistent weight-based dosing for infants. Epaned is also an option for patients who have difficulty swallowing enalapril tablets.
Enalapril inhibits angiotensin-converting enzyme (ACE), a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to angiotensin II. The beneficial effects of enalapril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system.
Epaned is already available as a 150mg/150mL powder for oral solution. The ready-to-use oral solution is available as 1mg/mL strength mixed berry flavor solution in 150mL bottles.
For more information call (855) 379-0382 or visit Epaned.com.